Dupixent Lawsuit Attorney

Attorney Michael Gunzburg

Do You Qualify? Here Is What We Look For

You may have a Dupixent lawsuit if all of the following apply to you:

• You used Dupixent (dupilumab), for eczema, asthma, nasal polyps, COPD, or another approved condition.
• You received at least two injections.
• You were later diagnosed with CTCL, including mycosis fungoides or Sézary syndrome.
• Your symptoms progressed while you were taking Dupixent, or your CTCL diagnosis was delayed.
• You are within your state's statute of limitations.

Not sure whether you qualify? Call 212-725-8500. We will review your situation at no cost and give you an honest assessment.

What Is Dupixent (Dupilumab)?

Dupixent is a biologic drug made by Sanofi and Regeneron. It works by blocking two proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), that play a role in inflammatory responses. By suppressing these signals, the drug reduces inflammation associated with certain conditions.

The FDA has approved Dupixent to treat:

• Moderate-to-severe atopic dermatitis (eczema), approved 2017
• Moderate-to-severe asthma, approved 2018
• Chronic rhinosinusitis with nasal polyps, approved 2019
• Eosinophilic esophagitis and prurigo nodularis, approved 2022
• COPD, approved 2024
• Chronic spontaneous urticaria and bullous pemphigoid, approved 2025

Dupixent is one of the most prescribed biologics in the world, with more than 1.4 million patients currently using it and quarterly sales exceeding €4 billion. Its widespread use is exactly why the emerging link to CTCL is so significant.

What Is Cutaneous T-Cell Lymphoma (CTCL)?

CTCL is a rare form of non-Hodgkin lymphoma. It develops when malignant T-cells, a type of white blood cell, migrate to the skin, causing abnormal growths that can spread over time.

The two most common subtypes are mycosis fungoides and Sézary syndrome. Symptoms can include:

• Red, scaly, or discolored patches and plaques on the skin
• Persistent itching that does not respond to standard treatments
• Thickened or hardened skin
• Swollen lymph nodes
• Fatigue

The Misdiagnosis Problem: CTCL Can Look Like Eczema

Early-stage CTCL often looks exactly like eczema or psoriasis. Red, itchy, scaly skin is a symptom of both. This creates a dangerous situation: doctors treating what appears to be eczema may prescribe Dupixent, which can temporarily reduce visible inflammation, all while the underlying cancer continues to progress.

By the time CTCL is correctly diagnosed, it may have advanced significantly. This delay is one of the central allegations in current Dupixent litigation: that Sanofi failed to warn doctors to rule out CTCL before prescribing the drug.

What Does the Research Show?

Multiple published studies point to a meaningful association between Dupixent use and CTCL. Here is what the science currently shows:

Peer-Reviewed Studies

Journal of the American Academy of Dermatology (April 2024): Researchers found that patients treated with dupilumab had more than four times the odds of developing CTCL compared with atopic dermatitis patients who were not treated with Dupixent (odds ratio: 4.10).

Dermatologic Therapy (August 2024): A separate study found a relative risk of 4.59 for CTCL among dupilumab users compared with matched controls.

European Respiratory Journal: Among asthma patients, Dupixent users had a hazard ratio of 1.79 for any lymphoma, and 4.58 for T/NK-cell lymphomas specifically.

Real-world pharmacovigilance data: Analyses of adverse event databases show that Dupixent users reported CTCL approximately 30 times more frequently than users of all other medications combined.

FDA Adverse Event Reporting System (FAERS)

The FDA's own adverse event database recorded 87,451 adverse events for dupilumab in 2025, with a disproportionate number of CTCL reports. The sheer volume of reports, combined with the research data, prompted the FDA to act.

Why Might Dupixent Cause or Contribute to CTCL?

Scientists are still working to understand the exact mechanism. Several theories have been proposed:

• Dupixent may impair the immune system's ability to detect and destroy early cancer cells by blocking IL-4/IL-13 signaling pathways.
• The drug may mask the visible symptoms of CTCL (the "unmasking effect"), delaying diagnosis while the cancer advances.
• IL-13 signaling may be redirected toward receptors that are overexpressed on malignant T-cells, potentially encouraging cancer cell growth.
• Delayed diagnosis caused by symptom suppression may allow CTCL to progress to a more advanced, and harder to treat, stage.

FDA Safety Signal and Regulatory Investigation

In March 2025, the FDA added Dupixent and CTCL to its Potential Signals of Serious Risks list, a formal step the agency takes when adverse event data suggests a drug may be causing a previously unrecognized harm. The decision was based on fourth-quarter 2024 FAERS data and came after the FDA received more than 300 CTCL reports linked to Dupixent.

The FDA has announced it is evaluating whether regulatory action is needed, which could include a mandatory label change or stronger warnings. As of February 2026, Dupixent's FDA-approved label still does not warn patients or physicians about the risk of CTCL or lymphoma. The current label mentions side effects like conjunctivitis, keratitis, and hypersensitivity, but says nothing about cancer.

This is the core of the failure-to-warn allegation: Sanofi and Regeneron had access to real-world data and research showing a CTCL risk. They chose not to update the label. Patients and their doctors were never told.

Where Does the Litigation Stand?

Dupixent lawsuits are in their early stages. Cases are being filed individually, this is not a class action. Each patient's medical history and circumstances are unique, which is why individual cases allow for a more tailored approach to damages.
Key developments to date:
October 2025: The first wrongful death lawsuit was filed in Tennessee. The plaintiff alleges her mother developed peripheral T-cell lymphoma shortly after beginning Dupixent and died months later.
January 2026: A second lawsuit was filed in Georgia by a woman who developed CTCL after using Dupixent.
February 2026: A motion was filed to consolidate Dupixent cases into a federal multidistrict litigation (MDL) in Georgia. This consolidation, if approved, would centralize pretrial proceedings while preserving each client's individual claim.

There are no jury verdicts or settlements yet. This is an early-stage investigation. Getting involved now means your case can be properly preserved and positioned before the litigation moves further along.

What Are Plaintiffs Alleging?
Dupixent caused or accelerated the development of CTCL.

Sanofi and Regeneron knew, or should have known, about the CTCL risk and failed to warn patients and physicians.

The drug's labeling did not instruct doctors to screen for or rule out CTCL before prescribing Dupixent.
Misleading marketing presented the drug as safe without disclosing the cancer risk.

What Compensation May Be Available?

Because there are no settlements yet, any figures at this stage are speculative. Legal analysts have discussed potential ranges based on comparable pharmaceutical litigations:

Early-stage CTCL: estimated $50,000–$300,000
Moderate disease: estimated $300,000–$500,000
Advanced cases: estimated $500,000–$1.5 million or more

These figures are not guarantees. Every case is different. What matters is building the strongest possible claim based on your specific diagnosis, medical history, and timeline. In addition to these estimates, damages could include medical expenses, lost wages, pain and suffering, and, in wrongful death cases, compensation for surviving family members.

If You Are Experiencing Symptoms or Have Already Been Diagnosed

Whether you are still experiencing skin symptoms or have already received a CTCL diagnosis, taking the right steps now can protect both your health and your legal rights.

1. Get a Thorough Medical Evaluation

If you have persistent or worsening skin symptoms, rashes, plaques, itching, swollen lymph nodes, that have not responded well to Dupixent, talk to your dermatologist or oncologist about ruling out CTCL. A skin biopsy is the standard diagnostic tool. Early detection matters.

2. Do Not Stop Dupixent Without Medical Guidance

We know this investigation raises serious concerns, but please consult your doctor before making any changes to your treatment. Filing a lawsuit does not require you to discontinue your medication.

3. Document Everything

Keep records of your Dupixent prescription dates, number of injections, symptom onset, physician visits, and all test results. This documentation is the foundation of your legal case.

4. Report to the FDA

You can submit an adverse event report through the FDA's MedWatch program at fda.gov/safety/medwatch. Your report contributes to the regulatory record and may help protect other patients.

5. Contact Michael Gunzburg, P.C.

The sooner you speak with an attorney, the better your chances of preserving evidence and meeting filing deadlines. Call 212-725-8500 for a free, no-obligation case evaluation.

Why Michael Gunzburg, P.C.?

Michael Gunzburg has spent 39+ years fighting for people who were hurt by someone else's negligence, including pharmaceutical companies that put profits before patient safety. His track record includes multimillion-dollar verdicts and settlements, and he has personally represented more than 100 clients in a national pharmaceutical products liability case.

This is not a volume-based operation. When you work with this firm, you work directly with Michael Gunzburg, not a case manager or paralegal. You will always know where your case stands.

No upfront fees. No hourly bills. We work on a contingency fee basis, you pay nothing unless we win or settle your case.

Learn more about our approach to product liability and defective drug cases.

Frequently Asked Questions About Dupixent Lawsuits

Does Dupixent cause cancer?

Published research shows a statistically significant association between Dupixent use and CTCL, with some studies finding the risk to be more than four times higher in Dupixent users. Whether Dupixent directly causes CTCL, or masks an existing cancer that then progresses, is still being investigated. What is clear is that the FDA considers this a potential serious safety signal and has launched a formal investigation.

Is there a Dupixent class action lawsuit?

No. Current cases are being filed as individual lawsuits because each person's medical history, diagnosis, and damages are unique. A motion has been filed to consolidate cases into a federal MDL (multidistrict litigation), which would centralize pretrial proceedings, but your claim would remain your own, not pooled with others as in a class action.

How long do I have to file a Dupixent lawsuit?

Statutes of limitations vary by state. In New York, you generally have three years from the date of injury or discovery of the injury to file. Other states have shorter windows. Do not assume you have time to wait, speak with an attorney as soon as possible to understand your specific deadline.

Should I stop taking Dupixent if I am concerned?

This is a decision to make with your doctor, not your attorney. Do not discontinue your medication without medical guidance. Pursuing legal action does not require you to stop treatment.

What compensation might I recover?

Potential damages include medical expenses (past and future), lost wages and earning capacity, pain and suffering, emotional distress, and, in cases involving a death, wrongful death damages for surviving family members. Punitive damages may also be available if the manufacturer's conduct is found to have been particularly reckless. No settlements have been reached yet, so specific figures are not available.

What if I used Dupixent for asthma, not eczema, do I still qualify?

Potentially yes. Research includes studies of asthma patients on Dupixent who developed T-cell lymphomas. If you used Dupixent for any approved indication and were later diagnosed with CTCL, your situation is worth reviewing.

Contact Michael Gunzburg, P.C., Free Case Review

The FDA is actively investigating. Lawsuits are being filed. Cases are beginning to consolidate. The window to get involved early, when evidence is fresh and your rights are fully protected, is now.

If you took Dupixent and were diagnosed with CTCL, call Michael Gunzburg, P.C. today. We will listen to what happened, explain your rights, and tell you honestly whether we think you have a case.

Call: 212-725-8500

Email: michael@gunzburglaw.com

Or contact us online to submit your information. We return calls within 24 hours.

No fee unless we recover for you. Your consultation is free and confidential.